FDA Issues Warning Letters to 30 Telehealth Firms Over 'Illegal' Compounded GLP-1 Sales

The Food and Drug Administration (FDA) on Tuesday sent 30 telehealth companies warning letters about their 'illegal' sales of compounded GLP-1s, building off increasing pressure to tamp down on the unauthorized distribution of these popular weight-loss and diabetes drugs. The agency stated these companies are illegally marketing compounded versions of semaglutide and tirzepatide, the active ingredients in brand-name drugs like Ozempic, Wegovy, and Mounjaro. The FDA warned that compounded drugs are not FDA-approved, may not meet safety and efficacy standards, and pose significant risks to patients. This action targets a rapidly growing online market where telehealth providers prescribe and ship compounded versions directly to consumers, often bypassing traditional pharmacies and medical oversight. The letters demand the companies cease violating the Federal Food, Drug, and Cosmetic Act. The crackdown reflects heightened regulatory scrutiny as demand for GLP-1 agonists surges, creating shortages and driving patients toward potentially unsafe alternatives. The FDA emphasized it is monitoring the situation and may take further enforcement actions, including injunctions or product seizures.